Evaluation of the Bioavailability of Pramlintide

PHASE2CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

June 30, 2002

Primary Completion Date

December 31, 2002

Study Completion Date

December 31, 2002

Conditions
Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2
Interventions
DRUG

Pramlintide acetate

Pramlintide acetate (AC137) injection is a clear, colorless, sterile solution for injection. It consists of pramlintide in sodium acetate buffer, pH 4.0, containing 43mg/mL mannitol as an iso-osmolality modifier and 2.25 mg/mL metacresol as a preservative. The strength of pramlintide is 1.0 mg/mL for SC injection and 0.6 mg/mL for IV bolus injection.

Trial Locations (4)

Unknown

Orlando Clinical Research Center, Orlando

New Orleans Center for Clinical Research, New Orleans

DaVita Clinical Research, Minneapolis

CEDRA Clinical Research, LLC, Austin

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY